Sophia Karagiannis, PhD

Professor of Translational Cancer Immunology at King's College London School of Medicine

Professor Sophia Karagiannis is a translational cancer immunologist with academic and biotechnology experience in the USA and UK. She heads a cancer antibody discovery team at King’s College London focused on the crosstalk between patient immunity and cancer and on the design of novel therapeutic agents. Key areas of research centre on patient-derived B cells and antibodies, Fc-engineered antibodies of different isotypes and antibody-drug conjugates for cancer therapy. Her group is the first to design, evaluate and translate anti-tumour IgE class antibodies from concept to clinical testing. Sophia is founder of Epsilogen Ltd, the first immuno-oncology company dedicated to developing IgE-based anti-cancer agents.